Text Size:AAA

SRC/Proto-oncogene c-Src  Protein, Antibody, ELISA Kit, cDNA Clone

Expression host: Baculovirus-Insect Cells  
50 µg 
20 µg 
Add to Cart
  • Slide 1
Description: Active  
Expression host: Baculovirus-Insect Cells  
50 µg 
20 µg 
Add to Cart
  • Slide 1

SRC/Proto-oncogene c-Src Related Area

SRC/Proto-oncogene c-Src Related Pathways

SRC/Proto-oncogene c-Src Related Protein, Antibody, cDNA Gene, and ELISA Kits

SRC/Proto-oncogene c-Src Related Protein, Antibody, cDNA Gene, and ELISA Kits

Featured Reagent Products

SRC/Proto-oncogene c-Src Summary & Protein Information

SRC/Proto-oncogene c-Src Background

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10028}.
Enzyme regulation: ENZYME REGULATION: Phosphorylation by CSK at Tyr-530 inhibits kinase activity. Inhibitory phosphorylation at Tyr-530 is enhanced by heme. Further phosphorylation by CDK1 partially reactivates CSK-inactivated SRC and facilitates complete reactivation by protein tyrosine phosphatase PTPRC. Integrin engagement stimulates kinase activity. Phosphorylation by PTK2/FAK1 enhances kinase activity. Butein and pseudosubstrate-based peptide inhibitors like CIYKYYF act as inhibitors. Phosphorylation at Tyr-419 increases kinase activity. {ECO:0000269|PubMed:14632929, ECO:0000269|PubMed:21036157, ECO:0000269|PubMed:7929427, ECO:0000269|PubMed:8759729, ECO:0000269|PubMed:9571170}.
Subunit structure: Interacts with DDEF1/ASAP1; via the SH3 domain. Interacts with CCPG1. Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with ERBB2, STAT1 and PNN. Interacts with DDR1, DDR2 and DAB2. Interacts with CDCP1, PELP1, TGFB1I1 and TOM1L2. Interacts with the cytoplasmic domain of MUC1, phosphorylates it and increases binding of MUC1 with beta-catenin. Interacts with RALGPS1; via the SH3 domain. Interacts with HEV ORF3 protein; via the SH3 domain. Interacts with CAV2 (tyrosine phosphorylated form). Interacts (via the SH3 domain and the protein kinase domain) with ARRB1; the interaction is independent of the phosphorylation state of SRC C-terminus. Interacts with ARRB1 and ARRB2. Interacts with SRCIN1. Interacts with NDFIP2 and more weakly with NDFIP1. Interacts with PIK3CA and/or PIK3C2B, PTK2/FAK1 and ESR1 (dimethylated on arginine). Interacts with FASLG. Interacts (via SH2 domain) with the 'Tyr-402' phosphorylated form of PTK2B/PYK2. Interacts (via SH2 domain) with FLT3 (tyrosine phosphorylated). Interacts with PDGFRA (tyrosine phosphorylated). Interacts with CSF1R. Interacts (via SH2 and SH3 domain) with TNK2. Interacts (via protein kinase domain) with the tyrosine phosphorylated form of RUNX3 (via runt domain). Interacts with TRAF3 (via RING-type zinc finger domain). Interacts with DDX58, MAVS and TBK1. Interacts (via SH2 domain) with GNB2L1/RACK1; the interaction is enhanced by tyrosine phosphorylation of GNB2L1 and inhibits SRC activity. Interacts with EPHB1; activates the MAPK/ERK cascade to regulate cell migration. Interacts with FCAMR. Interacts (via SH2 domain) with the 'Tyr-9' phosphorylated form of PDPK1. Interacts with AMOTL2; this interaction regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Interacts with TRAP1. Interacts with CBLC; the interaction is enhanced when SRC is phosphorylated at Tyr-419. {ECO:0000269|PubMed:10747847, ECO:0000269|PubMed:10753943, ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:11518702, ECO:0000269|PubMed:12091389, ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:15504032, ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16479011, ECO:0000269|PubMed:17202804, ECO:0000269|PubMed:17293535, ECO:0000269|PubMed:17525734, ECO:0000269|PubMed:18024423, ECO:0000269|PubMed:18657504, ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625, ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23564345, ECO:0000269|PubMed:8759729, ECO:0000269|PubMed:9584165, ECO:0000269|PubMed:9924018}.
Domain: The SH2 and SH3 domains are important for the intramolecular and intermolecular interactions that regulate catalytic activity, localization, and substrate recruitment.
Subcellular location: Cell membrane. Mitochondrion inner membrane. Nucleus. Cytoplasm, cytoskeleton. Note=Localizes to focal adhesion sites following integrin engagement. Localization to focal adhesion sites requires myristoylation and the SH3 domain.
Tissue specificity: Expressed ubiquitously. Platelets, neurons and osteoclasts express 5-fold to 200-fold higher levels than most other tissues.
Post-translational: Myristoylated at Gly-2, and this is essential for targeting to membranes. {ECO:0000269|PubMed:7525268}.; Dephosphorylated at Tyr-530 by PTPRJ (By similarity). Phosphorylated on Tyr-530 by c-Src kinase (CSK). The phosphorylated form is termed pp60c-src. Dephosphorylated by PTPRJ at Tyr-419. Normally maintained in an inactive conformation with the SH2 domain engaged with Tyr-530, the SH3 domain engaged with the SH2-kinase linker, and Tyr-419 dephosphorylated. Dephosphorylation of Tyr-530 as a result of protein tyrosine phosphatase (PTP) action disrupts the intramolecular interaction between the SH2 domain and Tyr-530, Tyr-419 can then become autophosphorylated, resulting in SRC activation. Phosphorylation of Tyr-530 by CSK allows this interaction to reform, resulting in SRC inactivation. CDK5-mediated phosphorylation at Ser-75 targets SRC to ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this enhances kinase activity. Phosphorylated by PTK2B/PYK2; this enhances kinase activity. {ECO:0000250, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:21442427, ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:6273838, ECO:0000269|PubMed:7525268}.; S-nitrosylation is important for activation of its kinase activity. {ECO:0000250}.; Ubiquitinated in response to CDK5-mediated phosphorylation. Ubiquitination mediated by CBLC requires SRC autophosphorylation at Tyr-419 and may lead to lysosomal degradation. {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:6273838}.
Involvement in disease: DISEASE: Note=SRC kinase activity has been shown to be increased in several tumor tissues and tumor cell lines such as colon carcinoma cells.
Sequence similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.; Contains 1 protein kinase domain. {ECO:0000255|PROSITE-ProRule:PRU00159}.; Contains 1 SH2 domain. {ECO:0000255|PROSITE-ProRule:PRU00191}.; Contains 1 SH3 domain. {ECO:0000255|PROSITE-ProRule:PRU00192}.
General information above from UniProt

Proto-oncogene tyrosine-protein kinase SRC is a hydrophobic protein belonging to the SRC family kinase including nine members that is a family of non-receptor tyrosine kinases. SRC protein may exist in different forms: C-SRC and V-SRC. C-SRC is only activated under certain circumstances where it is required such as growth factor signaling, while V-SRC is a constitutively active as opposed to normal SRC (C-SRC). Thus, V-SRC is an instructive example of an oncogene protein kinase whereas C-SRC is a proto-oncogene protein kinase. Inhibition of SRC with NR2A tyrosine phosphorylation mediated by PSD-95 may contribute to the lithium-induced downregulation of NMDA receptor function and provide neuroprotection against excitotoxicity.

SRC/Proto-oncogene c-Src Alternative Name

ASV,SRC1,c-SRC,p60-Src, [homo-sapiens]
ASV,c-SRC,p60-Src,RP5-823N20.1,SRC,SRC1, [human]
AW259666,pp60c-src,RP23-169M4.1,Src, [mouse]
AW259666,pp60c-src, [mus-musculus]

SRC/Proto-oncogene c-Src Related Studies

  • Juan Ma. et al., 2003, Neuroscience Letters. 348 (3): 185-189.
  • Czernilofsky AP. et al., 1980, Nature. 287: 198-203.
  • Beischlag TV. et al., 2002, Molecular and cellular biology. 22 (12): 4319-33.